Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: J AAPOS. 2013 Jun;17(3):229–234. doi: 10.1016/j.jaapos.2012.12.155

Table 1.

Major studies on supplemental oxygen in preterm infants

Studya Infant characteristics Intervention or study comparison Outcome
ELGAN (2002-2004)29 Infants born <28 wks GA Blood gases on first 2 of
 3 postnatal days		 Infants in greatest quartile for PaO2 or PCO2
 or lowest quartile for pH had increased
 risk of zone 1 and severe ROP
Pulse Oxygen Saturation
 Levels and Arterial
 Oxygen Tension Values
 (7/2005-11/2006)28 		Prospective comparison of
 PaO2 and SaO2 values
 (mean GA, 29.2 ± 5.2 wks;
 mean birth weight,
 1,338 ± 871.5 g)		 PaO2 and SaO2 measurements SaO2 of 85%-93% aligned with mean PaO2
 of 56 ± 14.7 mm Hg; SaO2 >93% aligned
 with mean PaO2 of 107.3 ± 59.3 mm Hg
 and >80 mm Hg 60% of time
STOP-ROP (2/94-3/99)37 Prethreshold ROP one eye 96%-99% SaO2 vs 89%-94% SaO2 No difference in ROP, adverse pulmonary
 outcomes in 96%-99% SaO2
SUPPORT
 (2/2005-2/2009)2,42 		24 to <28 wks’ GA 85%-89% SaO2 vs 91%-95% SaO2 Increased mortality in 85%-89% SaO2;
 of survivors, less ROP in 85%-89% SaO2
BOOST II (2006-2011)43 <28 wks’ GA 85%-89% SaO2 vs 91%-95% SaO2 Greater survival rate in 91%-95% SaO2

GA, gestational age.

a

BOOST, Benefits of Oxygen Saturation Targeting Study; ELGAN, Extremely Low Gestational Age Newborn; STOPROP, Supplemental Therapy with Oxygen to Prevent ROP Trial; SUPPORT, Surfactant, Positive Airway Pressure, Pulse Oximetry Randomized Trial.